Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston – Business Wire (press release)
|
Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
Business Wire (press release) Dr. von Hofe's Featured Presentation, Advantages of a Peptide-Based Vaccine Designed to Activate CD4+ T Cells in Cancer Immunotherapy, is scheduled for 8:30 am EDT on Wednesday, March 29 as part of the Peptides in Cancer Therapy symposium. |
